Archive for the Medical Studies Category

Mushroom Glucans (PSP & PSK) in Cancer Treatments

By on January 9, 2012
This entry is filed under General Information, Medical Studies, Properties, PSK, PSP, The Immune System, Treatments and tagged , , .

Another narrative on the positive effects of Coriolus extracts over other mushrooms. Paragraph is highlighted…
Immunoceuticals can be considered as substances having immunotherapeutic efficacy when taken orally. More than 50 mushroom species have yielded potential immunoceuticals that exhibit anticancer activity in vitro or in animal models and of these, six have been investigated in human cancers. All are non-toxic and very well tolerated. Lentinan and schizophyllan have little oral activity. Active Hexose Correlated Compound (AHCC) is poorly defined but has shown early clinical promise. Maitake D-Fraction has limited proof of clinical efficacy to date, but controlled research is underway.

Two proteoglycans from Coriolus versicolor – PSK (Polysaccharide-K) and PSP (Polysaccharide-Peptide – have demonstrated the most promise. In Japanese trials since 1970, PSK significantly extended survival at five years or beyond in cancers of the stomach, colon-rectum, esophagus, nasopharynx, and lung (non-small cell types), and in a HLA B40-positive breast cancer subset. PSP was subjected to Phase II and Phase III trials in China. In double-blind trials, PSP significantly extended five-year survival in esophageal cancer. PSP significantly improved quality of life, provided substantial pain relief, and enhanced immune status in 70-97 percent of patients with cancers of the stomach, esophagus, lung, ovary, and cervix. PSK and PSP boosted immune cell production, ameliorated chemotherapy symptoms, and enhanced tumor infiltration by dendritic and cytotoxic T-cells. Their extremely high tolerability, proven benefits to survival and quality of life, and compatibility with chemotherapy and radiation therapy makes them well suited for cancer management regimens.
Altern Med Rev 2000 Feb;5(1):4-27
Publication Types: Review, tutorial
PMID: 10696116, UI: 20161032

Sorce: x5power.com

Effects and Mechanisms Of PSK & PSP Against Cancers

By on January 6, 2012
This entry is filed under Breast Cancer, Colorectal Cancer, Gastric Cancer, General Information, Lung Cancer, Medical Studies, Oesophageal Cancer, Properties and tagged , , , , , , .

Found this recently in a French scientific reference site ( cat.inist.fr )

Polysaccharide-K (polysaccharide-Kureha; PSK), also known as krestin, is a unique protein-bound polysaccharide, which has been used as a chemoimmunotherapy agent in the treatment of cancer in Asia for over 30 years. PSK and Polysaccharopeptide (PSP) are both protein-bound polysaccharides which are derived from the CM-101 and COV-1 strains of the fungus Coriolus versicolor by Japanese and Chinese researchers, respectively. Both polysaccharide preparations have documented anticancer activity in vitro, in vivo and in human clinical trials, though PSK has been researched longer and has therefore undergone more thorough laboratory, animal and clinical testing. Several randomized clinical trials have demonstrated that PSK has great potential as an adjuvant cancer therapy agent, with positive results seen in the adjuvant treatment of gastric, esophageal, colorectal, breast and lung cancers.

These studies have suggested the efficacy of PSK as an immunotherapy or biological response modifier (BRM). BRMs potentially have the ability to improve the host versus tumor response, thereby increasing the ability of the host to defend itself from tumor progression. The mechanisms of biological response modification by PSK have yet to be clearly and completely elucidated. Some studies suggest that PSK may act to increase leukocyte activation and response through up-regulation of key cytokines. Indeed, natural killer (NK) and lymphocyte-activated killer (LAK) cell activation has been demonstrated in vivo and in vitro, and recent genetic studies reveal increased expression of key immune cytokines in response to treatment with PSK. An antimetastatic action of PSK has also been demonstrated and is perhaps attributed to its potential to inhibit metalloproteinases and other enzymes involved in metastatic activity. PSK has also been shown to cause differentiation of leukemic cells in vitro, and this effect has been attributed to induction of differentiation cytokines.

PSK has further been shown to have antioxidant capacity which may allow it to play a role as a normal tissue chemo- and radio- protector when used in combination with adjuvant or definitive chemotherapy and/or radiotherapy in the treatment of cancer, while it may also enable it to defend the host from oxidative stress. Interestingly, studies have also shown that PSK may actually inhibit carcinogenesis by inhibiting the action of various carcinogens on vulnerable cell lines. This action of PSK may play a role in preventing second primary tumors when an inducing agent, such as tobacco or asbestos, is suspected and may also prevent second malignancies due to the carcinogenic effects of radiotherapy and cytotoxic chemotherapy. Another very important aspect of chemoimmunotherapy, in general, is that it may be used on debilitated patients such as those with AIDS and the elderly who might otherwise be denied potentially helpful adjuvant cytotoxic chemotherapy. Further determination of the mechanisms of these anti-cancer, immunostimulating and biological response modifying effects of PSK as well as of other protein-bound polysaccharides is certainly warranted. Indeed, with modem cellular and molecular biology techniques, a better understanding of the specific molecular effects of PSK on tumor cells as well as leukocytes may be determined.

 

Source: International Institute of Anticancer Research, Attiki, GRECE  (1980) (Revue) 2002, vol. 22, no3, pp. 1737-1754 (174 ref.)

PSP & Prostate Cancer

By on October 21, 2011
This entry is filed under inForce Platinum, Medical Studies, Prostate Cancer, PSP and tagged , , , , , .

For all articles regarding Prostate Cancer treatments and studies and Coriolus Versicolor  – See here

Prostate Cancer & PSP

Recent evidence suggested that prostate cancer stem/progenitor cells (CSC) are responsible for cancer initiation as well as disease progression. Unfortunately, conventional therapies are only effective in targeting the more differentiated cancer cells and spare the CSCs. Here, we report that PSP, an active component extracted from the mushroom Turkey tail (also known as Coriolus versicolor), is effective in targeting prostate CSCs. We found that treatment of the prostate cancer cell line PC-3 with PSP led to the down-regulation of CSC markers (CD133 and CD44) in a time and dose-dependent manner. Meanwhile, PSP treatment not only suppressed the ability of PC-3 cells to form prostaspheres under non-adherent culture conditions, but also inhibited their tumorigenicity in vivo, further proving that PSP can suppress prostate CSC properties. To investigate if the anti-CSC effect of PSP may lead to prostate cancer chemoprevention, transgenic mice (TgMAP) that spontaneously develop prostate tumors were orally fed with PSP for 20 weeks. Whereas 100% of the mice that fed with water only developed prostate tumors at the end of experiment, no tumors could be found in any of the mice fed with PSP, suggesting that PSP treatment can completely inhibit prostate tumor formation. Our results not only demonstrated the intriguing anti-CSC effect of PSP, but also revealed, for the first time, the surprising chemopreventive property of oral PSP consumption against prostate cancer.

PSP – “A New Form Of Biological Response Modifier”

By on October 16, 2011
This entry is filed under Buy Best Coriolus Products, General Information, inForce Platinum, Medical Studies, PSP, The Immune System and tagged , , , , .

Coriolus Versicolor PSP is a biological response modifier. here is more research on PSP

Pharmacodynamic studies prove that PSP has a very obvious effect of strengthening health and energy to eliminate substances and is a new type of BRM (Biological response Modifier)

  1. PSP can enhance the immune function of a normal body.
    • Promote the expression of IL-6 gene of peripheral blood lymphocytes (PBL) in humans and hence induce the production of interlukin 6 (IL-6), and also activate white blood cells to increase the production of interferon alpha and game by 2 to 4 times.
    • Greatly increase the phagocytic index and raise HC50, IgG and PFC values in mice; accelerate PBL from G1 to S period and promote the proliferation of PBL.
    • Promote the proliferation of T-lymphoctes and pre-T cells in the thymus and spleen.
  1. PSP can antagonize tumour-induced immuno-suppression in animals
    • Arrest the atrophy of thymus in sarcoma bearing mice.
    • Antagonize the swelling of liver dur to Ehrlich ascites carcinoma.
    • Counteract the inhibition effect on antibody caused by sarcoma in mice.
    • Raise the value of serum complement C3 in sarcoma bearing mice.
  1. PSP can antagonize immuno-suppression caused by chemotherapeutic drugs.
    • Obviously antagonize the lowering action of white blood cells caused by cyclophosphamide and shorten the recovery time of WBC.
    • Obviously counteract the inhibitory action of cyclophosphamide on interleukin-2 (IL-2) and NK cells.
    • Restore the delayed type hypersensitivity (DTH) reaction inhibited by cyclophosphamide.
  1. PSP can inhibit the growth of cancer cells in men and animals.
    • PSP (50mg/kg, ip or po) can inhibit the growth of sarcoma 180 in mice. The inhibition rates are 46-68%.
    • A test using radioactive precursors shows that PSP (100microgram/ml) can inhibit the synthesis of nucleic acid of ehrlich ascites carcinoma. The inhibition rates of RNA and DNA are 51% and 45% respectively.
    • PSP can inhibit the growth of P388 leukemia cells, myeloma cells, hepatoma, Lewis lung cancer in mice. It can also inhibit the growth of human liver cancer, colon cancer, nasopharyngeal carcinoma, stomach cancer, human lung adenocarcinoma, monocytic leukemia and human skin histiocytic lymphoma. It can also cause the swelling of cancer cells and chromosome aggregation
    • That antilymphatic serum (ALS) can counteract the inhibitory effect of PSP on sarcoma provides counter-evidence that anti-tumour activity of PSP is related to the increase of T-lymphocytes.
  1. Other effects of PSP.
    • Obviously improve the appetite of mice being administered with cyclophosphamide.
    • Obviously decrease the painful reaction of animal caused by hot plate, acetic acid and electric stimulation.
    • inhibit the central nervous system and decrease the spontaneous activity of mice.
    • In terms of the survival time of mice in oxygen-lacking conditions, PSP test group has a much higher ability of anoxia tolerance.

(Source: http://psp-research.com)

Buy 100% PSP (Dr Yang extraction) inForce Platinum or go to shop above.

Coriolus PSP Found To Supress Prostate Tumours – QUT

By on June 1, 2011
This entry is filed under Medical Studies, News, Prostate Cancer, PSP and tagged .

Coriolus PSP (Polysaccharide Peptide), used in Asia for its medicinal benefits has been found to be 100 per cent effective in suppressing prostate tumour development in mice during early trials, new Queensland University of Technology (QUT) research shows.

The compound, polysaccharopeptide (PSP), which is extracted from the ‘turkey tail’ mushroom, was found to target prostate cancer stem cells and suppress tumour formation in mice, an article written by senior research fellow Dr Patrick Ling in the international scientific journal PLoS ONE said.

Dr Ling, from the Australian Prostate Cancer Research Centre-Queensland and Institute for Biomedical Health & Innovation (IHBI) at QUT, said the results could be an important step towards fighting a disease that kills 3000 Australian men a year.

“The findings are quite significant,” Dr Ling said.

“What we wanted to demonstrate was whether that compound could stop the development of prostate tumours in the first place.

“In the past, other inhibitors tested in research trials have been shown to be up to 70 per cent effective, but we’re seeing 100 per cent of this tumour prevented from developing with PSP.

“Importantly, we did not see any side effects from the treatment.”

Dr Ling said conventional therapies were only effective in targeting certain cancer cells, not cancer stem cells, which initiated cancer and caused the disease to progress.

During the research trial, which was done in collaboration with The University of Hong Kong and Provital Pty Ltd, transgenic mice that developed prostate tumours were fed PSP for 20 weeks.

Dr Ling said no tumours were found in any of the mice fed PSP, whereas mice not given the treatment developed prostate tumours. He said the research suggested that PSP treatment could completely inhibit prostate tumour formation.

“Our findings support that PSP may be a potent preventative agent against prostate cancer, possibly through targeting of the prostate cancer stem cell population,” he said.

He said PSP had been previously shown to possess anti-cancer properties, and ‘turkey tail’ mushrooms (known as Coriolus versicolor or Yun-zhi) had been widely used in Asia for medicinal benefits.

However, Dr Ling said it was the first time it had been demonstrated that PSP had anti-cancer stem cell effects.

Although ‘turkey tail’ mushrooms had valuable health properties, Dr Ling said it would not be possible to get the same benefit his research showed from simply eating them.

A fundraiser has been organised in September to support further tests for the therapeutic potential of PSP against prostate tumours either alone or in combination with other anti-cancer compounds.

Source: (www.news.qut.edu.au)

Page 1 of 512345
Rss Feed Tweeter button Facebook button Technorati button Linkedin button Webonews button Delicious button Digg button